Abstract:Mushroom polysaccharides have great potential in anti-diabetes. The fruiting body of Tremella fuciformis is rich in polysaccharides. However, few studies have so far performed on the T. fuciformis-derived polysaccharides (TPs) in anti-diabetes potential. Our previous studies showed that a novel TPs with medium molecular weights exhibited the highest anti-skin aging activities among the test samples in D-galactose-treated mice. In the present study, the effects of this novel TPs, named TP, on the high-fat diet and streptozotocin-treated mice were assessed, and its potential biological mechanisms were explored by metagenomic and transcriptomic analyses. Oral administration of TP markedly reduced blood glucose and TG levels, alleviated emaciation, improved anti-oxidant capacity, and protected the functions of β-cells at a dose of 100 mg/kg in diabetic mice. Meanwhile, the taxonomic compositions and functional properties of fecal microbiota were altered considerably by TP, as evidenced by a partial restoration of the imbalanced gut microbiota and the higher abundances of Bacteroides, Phocaeicola, Bifidobacterium, and Alistipes compared to the model mice, corresponding to the upregulations of four enriched KEGG pathways of microbial communities such as digestive system, cardiovascular disease, infectious disease: parasitic, and cell growth and death. Further transcriptomic analysis of liver tissues identified 35 enriched KEGG pathways associated with metabolisms and cellular signaling processes in response to TP. These results demonstrated the biological mechanisms underlying the hypoglycemic and hypotriglyceridemic activities of TP. The findings expanded our understanding of the anti-diabetic mechanisms for mushroom polysaccharides and provided new clues for future studies.

Metagenomic and transcriptomic profiling of the hypoglycemic and hypotriglyceridemic actions of Tremella fuciformis-derived polysaccharides in high-fat diet and streptozotocin-treated mice